Utah is currently home to 1221 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Salt Lake City, Murray, Ogden and West Jordan. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Hand Sanitizer Use for Herpes Simplex Virus-1
NCT06135844
Recruiting
The purpose of this pilot study is to determine if the use of Purell hand sanitizer alters the duration, level of pain and discomfort during treatment, and the size of the HSV-1 lesion. The duration of an HSV-1 (herpes) lesion is the primary endpoint for this study. Size, pain, and discomfort are the secondary endpoints.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
11/13/2023
Locations: Cotton Creek Dental, Saint George, Utah
Conditions: Virus, HSV-1, Herpes Simplex 1, Herpes Simplex Labialis
Register for Updates
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
NCT04775745
Recruiting
This is a phase I, multi-center, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and clinical activity of LP-168 in subjects with relapsed or refractory B-cell malignancies. LP-168 is a small molecule inhibitor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/10/2023
Locations: Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
Conditions: CLL/SLL, Waldenstrom Macroglobulinemia, Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Hairy Cell Leukemia
Register for Updates
Comparative Pharmacokinetic Study of Three Abatacept Products in Male Normal Healthy Volunteers by the Subcutaneous Route
NCT06126042
Recruiting
This is a randomised, double-blind, single dose, parallel groups study to compare the PK, immunogenicity, and safety of 3 abatacept products (DRL_AB, RP and RMP) in male NHV.
Gender:
MALE
Ages:
Between 18 years and 50 years
Trial Updated:
11/08/2023
Locations: ICON, Salt Lake City, Utah
Conditions: Rheumatoid Arthritis
Register for Updates
Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy
NCT05004129
Recruiting
This is an open-label phase 2/3 study for individuals with Congenital Myotonic Dystrophy (Congenital DM1) who participated in the preceding AMO-02-MD-2-003 study or individuals with either Congenital or Childhood Onset DM1 who are treatment naïve.
Gender:
ALL
Ages:
Between 6 years and 45 years
Trial Updated:
11/05/2023
Locations: University of Utah Clinical Neurosciences Center, Salt Lake City, Utah
Conditions: Congenital Myotonic Dystrophy
Register for Updates
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
NCT05082519
Recruiting
This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients with B-ALL. Chemotherapy during the first month causes large gains in body fat in most people, even those who start chemotherapy at a healthy weight. This study is being done to find out if caloric restriction achieved by a personalized nutritional menu and exercise plan during routine chemotherapy... Read More
Gender:
ALL
Ages:
Between 10 years and 25 years
Trial Updated:
10/25/2023
Locations: Primary Children's Hospital, Salt Lake City, Utah
Conditions: B-cell Acute Lymphoblastic Leukemia, Obesity
Register for Updates
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
NCT05183646
Recruiting
DMX-200 (repagermanium) is a C-C chemokine receptor type 2 (CCR2) inhibitor that, when administered concurrently with an ARB, is designed to inhibit recruitment of monocytes implicated in the inflammatory chemokine environment of chronic disease. The purpose of this pivotal randomized double-blind study is to investigate the efficacy and safety of DMX-200 120 mg twice daily (BID) compared with placebo over a treatment period of 104 weeks in adult patients with FSGS who are being treated with an... Read More
Gender:
ALL
Ages:
Between 12 years and 80 years
Trial Updated:
10/24/2023
Locations: ACTION3 Investigational Site 7, Salt Lake City, Utah
Conditions: FSGS
Register for Updates
Biological Sex and CTEPH-related RV Dysfunction and Recovery (BIOSPHeRe)
NCT06105242
Recruiting
1. To identify biological sex differences in baseline RV function in CTEPH 2. To identify biological sex differences in recovery of RV function after PTE surgery in CTEPH 3. To determine if sex hormone levels relate to RV function at CTEPH diagnosis and during recovery after PTE.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/23/2023
Locations: Intermountain Medical Center, Murray, Utah
Conditions: CTEPH
Register for Updates
An ACT Website for College Students With Insomnia
NCT06094751
Recruiting
College students experience higher rates of insomnia compared the general population, and accessibility and availability for the appropriate intervention is difficult due limited resources available to them in a college environment. Theorefore, it is vital to offer an intervention that can be just as effective yet more accessible than other available treatments targeting insomnia. That is why this study will investigate the efficacy and feasibility of an online ACT intervention for insomnia amon... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/20/2023
Locations: Utah State University, Logan, Utah
Conditions: Insomnia
Register for Updates
Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients
NCT05586971
Recruiting
The aim of this 12-month randomized multi-regional double-blind parallel group allopurinol and placebo-controlled phase 3 study is to assess the efficacy and safety of three different doses of Tigulixostat in gout patients with hyperuricemia.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
10/17/2023
Locations: Cope Family Medicine/CCT Research, Bountiful, Utah
Conditions: Gout, Hyperuricemia, Gout Flare, Tophi
Register for Updates
Smart Ankle-Foot Orthosis to Improve Stroke Outcomes: Smart AFO
NCT05619484
Recruiting
The Smart Ankle-Foot Orthosis (Smart AFO) system is an investigational system that combines a diagnostic ankle-foot orthosis with a mobile application to assist clinicians in optimizing an AFO user's gait by adjusting AFO stiffness and range of motion settings, and quantifying functional walking improvements in post-stroke individuals. The purpose of the clinical testing is to evaluate the Smart AFO system with its target users: post-stroke AFO users and orthotists. This may include, but is not... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/06/2023
Locations: University of Utah, Salt Lake City, Utah
Conditions: Stroke
Register for Updates
Post-Approval Study of the TREO Abdominal Stent-Graft System
NCT04697784
Recruiting
The purpose of this study is to determine the long-term performance of the TREO Abdominal Stent-Graft as a treatment for patients with Infrarenal Abdominal Aortic Aneurysms or Aorto-iliac Aneurysms.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/27/2023
Locations: University of Utah Hospital, Salt Lake City, Utah
Conditions: Abdominal Aortic Aneurysm
Register for Updates
A Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of IMS001 in Subjects With Multiple Sclerosis
NCT04956744
Recruiting
This is a Phase 1 study of IMS001, given as a single dose to subjects with Multiple Sclerosis who experience inadequate response and/or intolerability to disease modifying treatments. IMS001 is a human embryonic cell derived (hESC) mesenchymal stem cell (MSC). MSCs have the potential to modulate disease course.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
09/26/2023
Locations: Rocky Mountain MS Clinic, Salt Lake City, Utah
Conditions: Multiple Sclerosis
Register for Updates